Platshon Scott sold 15,292 shares of Zymeworks Inc. at $24.95 for −$382k on Nov 18, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
EVP, Chief Business Officer
EVP, Chief Business Officer
Filed Nov 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$381,535.40Shares × reported price
Shares traded
15,292Common Stock
Price per share
$24.95Reported price. Read footnotes for ranges.
% of reported position traded
41.29%This security and ownership context
Holdings after
21,745Direct
Trade date
Nov 18, 2026Sell
Filed
Nov 18, 2026, 3:18 PM ET0-day reporting delay
Accession
0001816539-26-000005Code S · Transaction 405537
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 37,037 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 18, 2026Option exercise37,037$0.00$0Trade 405536
Nov 18, 2026Option exercise37,037$0.00$0Trade 405538
3 transaction rows in this filing. Joint filers share the same rows.

ZYME price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ZYME · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 25, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −1.2%1w ago +15%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 18, 2025. F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.88 to $25.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F5: RSUs granted November 18, 2025; vest in three equal annual instalments beginning November 18, 2026.